The HOPE Heart Outcomes and Prevention Evaluation trial found a higher risk of cardiovascular death in patients with serum creati-nine levels between 1.4 and 2.3 mg/dl, which corresponded to a prevalence of 11.4% vs. 6.6% in healthy patients; with a 1.4 risk 95% CI 1.16-1.69 regardless of treatment.
En el estudio Heart Outcomes and Preuention Eualuation HOPE se encontró un riesgo elevado de muerte cardiovascular en pacientes con niveles séricos de creatinina entre 1,4 y 2,3 mg/dl, lo cual correspondió a una prevalencia del 11,4% vs.